Provided by Tiger Trade Technology Pte. Ltd.

Therapeutics

4.23
-0.2400-5.37%
Pre-market: 4.290.0600+1.42%04:23 EDT
Volume:819.74K
Turnover:3.49M
Market Cap:132.36M
PE:-1.02
High:4.44
Open:4.44
Low:4.21
Close:4.47
52wk High:50.40
52wk Low:4.21
Shares:31.29M
Float Shares:18.39M
Volume Ratio:1.13
T/O Rate:4.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1300
EPS(LYR):-2.8503
ROE:-59.21%
ROA:-37.36%
PB:0.60
PE(LYR):-1.48

Loading ...

Whitehawk Therapeutics presents PTK7 data at WCLC 2026

TIPRANKS
·
Sep 14

Ceryvyn Therapeutics Issues 7 Million Unquoted Options in Capital Management Move

TIPRANKS
·
Sep 14

Top Brass Double Down on Relmada Therapeutics in Bold Insider Bet

TIPRANKS
·
Sep 12

Relmada Therapeutics Shares Rise After CEO, CFO Buy 200,000 Shares Each

MT Newswires Live
·
Sep 12

Summit Therapeutics Advances Ivonescimab Combo Into Pivotal Bladder Cancer Trial

TIPRANKS
·
Sep 12

TScan Therapeutics Launches Executive Retention Incentive Program

TIPRANKS
·
Sep 11

Tempest Therapeutics announces $7.5M private placement

TIPRANKS
·
Sep 11

Dianthus Therapeutics Price Target Announced at $135.00/Share by JP Morgan

Dow Jones
·
Sep 11

Tempest Therapeutics Announces Up to $7.5 Million Private Placement

GlobeNewswire
·
Sep 11

NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System

MT Newswires Live
·
Sep 11

JPMorgan Initiates Coverage on Dianthus Therapeutics With Overweight Rating

MT Newswires Live
·
Sep 11

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

GlobeNewswire
·
Sep 11

Ovid Therapeutics price target raised to $5 from $4 at H.C. Wainwright

TIPRANKS
·
Sep 11

Outlook Therapeutics is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Sep 11

Serina Therapeutics: Early SER-252 Efficacy Signal and Strategic Positioning Support Unchanged $8 Price Target and Buy Rating

TIPRANKS
·
Sep 11

Xcell Therapeutics Trims Board as Independent Director Resigns

TIPRANKS
·
Sep 11

PYC Therapeutics Says First Patient Dosed in Open-Label Extension of Drug Candidate Study in Polycystic Kidney Disease

MT Newswires Live
·
Sep 11

Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus After OSC Review

TIPRANKS
·
Sep 11

Whitehawk Therapeutics Adds Oncology Leader to Board

TIPRANKS
·
Sep 11

Cardiol Therapeutics files $150M preliminary base shelf prospectus

TIPRANKS
·
Sep 11